Stem-cell gene therapy for the Wiskott-Aldrich syndrome

Kaan Boztug, Manfred Schmidt, Adrian Schwarzer, Pinaki P. Banerjee, Inés Avedillo Díez, Ricardo A. Dewey, Marie Böhm, Ali Nowrouzi, Claudia R. Ball, Hanno Glimm, Sonja Naundorf, Klaus Kühlcke, Rainer Blasczyk, Irina Kondratenko, L. Máródi, Jordan S. Orange, Christof Von Kalle, Christoph Klein

Research output: Contribution to journalArticle

353 Citations (Scopus)

Abstract

The Wiskott-Aldrich syndrome (WAS) is an X-linked recessive primary immunodeficiency disorder associated with thrombocytopenia, eczema, and autoimmunity. We treated two patients who had this disorder with a transfusion of autologous, genetically modified hematopoietic stem cells (HSC). We found sustained expression of WAS protein expression in HSC, lymphoid and myeloid cells, and platelets after gene therapy. T and B cells, natural killer (NK) cells, and monocytes were functionally corrected. After treatment, the patients' clinical condition markedly improved, with resolution of hemorrhagic diathesis, eczema, autoimmunity, and predisposition to severe infection. Comprehensive insertion-site analysis showed vector integration that targeted multiple genes controlling growth and immunologic responses in a persistently polyclonal hematopoiesis. (Funded by Deutsche Forschungsgemeinschaft and others; German Clinical Trials Register number, DRKS00000330.).

Original languageEnglish
Pages (from-to)1918-1927
Number of pages10
JournalNew England Journal of Medicine
Volume363
Issue number20
DOIs
Publication statusPublished - Nov 11 2010

Fingerprint

Wiskott-Aldrich Syndrome
Eczema
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Autoimmunity
Genetic Therapy
Stem Cells
Wiskott-Aldrich Syndrome Protein
Hemorrhagic Disorders
Hematopoiesis
Myeloid Cells
Natural Killer Cells
Thrombocytopenia
Monocytes
B-Lymphocytes
Blood Platelets
Clinical Trials
Lymphocytes
T-Lymphocytes
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Boztug, K., Schmidt, M., Schwarzer, A., Banerjee, P. P., Díez, I. A., Dewey, R. A., ... Klein, C. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. New England Journal of Medicine, 363(20), 1918-1927. https://doi.org/10.1056/NEJMoa1003548

Stem-cell gene therapy for the Wiskott-Aldrich syndrome. / Boztug, Kaan; Schmidt, Manfred; Schwarzer, Adrian; Banerjee, Pinaki P.; Díez, Inés Avedillo; Dewey, Ricardo A.; Böhm, Marie; Nowrouzi, Ali; Ball, Claudia R.; Glimm, Hanno; Naundorf, Sonja; Kühlcke, Klaus; Blasczyk, Rainer; Kondratenko, Irina; Máródi, L.; Orange, Jordan S.; Von Kalle, Christof; Klein, Christoph.

In: New England Journal of Medicine, Vol. 363, No. 20, 11.11.2010, p. 1918-1927.

Research output: Contribution to journalArticle

Boztug, K, Schmidt, M, Schwarzer, A, Banerjee, PP, Díez, IA, Dewey, RA, Böhm, M, Nowrouzi, A, Ball, CR, Glimm, H, Naundorf, S, Kühlcke, K, Blasczyk, R, Kondratenko, I, Máródi, L, Orange, JS, Von Kalle, C & Klein, C 2010, 'Stem-cell gene therapy for the Wiskott-Aldrich syndrome', New England Journal of Medicine, vol. 363, no. 20, pp. 1918-1927. https://doi.org/10.1056/NEJMoa1003548
Boztug K, Schmidt M, Schwarzer A, Banerjee PP, Díez IA, Dewey RA et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. New England Journal of Medicine. 2010 Nov 11;363(20):1918-1927. https://doi.org/10.1056/NEJMoa1003548
Boztug, Kaan ; Schmidt, Manfred ; Schwarzer, Adrian ; Banerjee, Pinaki P. ; Díez, Inés Avedillo ; Dewey, Ricardo A. ; Böhm, Marie ; Nowrouzi, Ali ; Ball, Claudia R. ; Glimm, Hanno ; Naundorf, Sonja ; Kühlcke, Klaus ; Blasczyk, Rainer ; Kondratenko, Irina ; Máródi, L. ; Orange, Jordan S. ; Von Kalle, Christof ; Klein, Christoph. / Stem-cell gene therapy for the Wiskott-Aldrich syndrome. In: New England Journal of Medicine. 2010 ; Vol. 363, No. 20. pp. 1918-1927.
@article{0c4531cafde3442da13cccfa345f42ad,
title = "Stem-cell gene therapy for the Wiskott-Aldrich syndrome",
abstract = "The Wiskott-Aldrich syndrome (WAS) is an X-linked recessive primary immunodeficiency disorder associated with thrombocytopenia, eczema, and autoimmunity. We treated two patients who had this disorder with a transfusion of autologous, genetically modified hematopoietic stem cells (HSC). We found sustained expression of WAS protein expression in HSC, lymphoid and myeloid cells, and platelets after gene therapy. T and B cells, natural killer (NK) cells, and monocytes were functionally corrected. After treatment, the patients' clinical condition markedly improved, with resolution of hemorrhagic diathesis, eczema, autoimmunity, and predisposition to severe infection. Comprehensive insertion-site analysis showed vector integration that targeted multiple genes controlling growth and immunologic responses in a persistently polyclonal hematopoiesis. (Funded by Deutsche Forschungsgemeinschaft and others; German Clinical Trials Register number, DRKS00000330.).",
author = "Kaan Boztug and Manfred Schmidt and Adrian Schwarzer and Banerjee, {Pinaki P.} and D{\'i}ez, {In{\'e}s Avedillo} and Dewey, {Ricardo A.} and Marie B{\"o}hm and Ali Nowrouzi and Ball, {Claudia R.} and Hanno Glimm and Sonja Naundorf and Klaus K{\"u}hlcke and Rainer Blasczyk and Irina Kondratenko and L. M{\'a}r{\'o}di and Orange, {Jordan S.} and {Von Kalle}, Christof and Christoph Klein",
year = "2010",
month = "11",
day = "11",
doi = "10.1056/NEJMoa1003548",
language = "English",
volume = "363",
pages = "1918--1927",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "20",

}

TY - JOUR

T1 - Stem-cell gene therapy for the Wiskott-Aldrich syndrome

AU - Boztug, Kaan

AU - Schmidt, Manfred

AU - Schwarzer, Adrian

AU - Banerjee, Pinaki P.

AU - Díez, Inés Avedillo

AU - Dewey, Ricardo A.

AU - Böhm, Marie

AU - Nowrouzi, Ali

AU - Ball, Claudia R.

AU - Glimm, Hanno

AU - Naundorf, Sonja

AU - Kühlcke, Klaus

AU - Blasczyk, Rainer

AU - Kondratenko, Irina

AU - Máródi, L.

AU - Orange, Jordan S.

AU - Von Kalle, Christof

AU - Klein, Christoph

PY - 2010/11/11

Y1 - 2010/11/11

N2 - The Wiskott-Aldrich syndrome (WAS) is an X-linked recessive primary immunodeficiency disorder associated with thrombocytopenia, eczema, and autoimmunity. We treated two patients who had this disorder with a transfusion of autologous, genetically modified hematopoietic stem cells (HSC). We found sustained expression of WAS protein expression in HSC, lymphoid and myeloid cells, and platelets after gene therapy. T and B cells, natural killer (NK) cells, and monocytes were functionally corrected. After treatment, the patients' clinical condition markedly improved, with resolution of hemorrhagic diathesis, eczema, autoimmunity, and predisposition to severe infection. Comprehensive insertion-site analysis showed vector integration that targeted multiple genes controlling growth and immunologic responses in a persistently polyclonal hematopoiesis. (Funded by Deutsche Forschungsgemeinschaft and others; German Clinical Trials Register number, DRKS00000330.).

AB - The Wiskott-Aldrich syndrome (WAS) is an X-linked recessive primary immunodeficiency disorder associated with thrombocytopenia, eczema, and autoimmunity. We treated two patients who had this disorder with a transfusion of autologous, genetically modified hematopoietic stem cells (HSC). We found sustained expression of WAS protein expression in HSC, lymphoid and myeloid cells, and platelets after gene therapy. T and B cells, natural killer (NK) cells, and monocytes were functionally corrected. After treatment, the patients' clinical condition markedly improved, with resolution of hemorrhagic diathesis, eczema, autoimmunity, and predisposition to severe infection. Comprehensive insertion-site analysis showed vector integration that targeted multiple genes controlling growth and immunologic responses in a persistently polyclonal hematopoiesis. (Funded by Deutsche Forschungsgemeinschaft and others; German Clinical Trials Register number, DRKS00000330.).

UR - http://www.scopus.com/inward/record.url?scp=78149482538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149482538&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1003548

DO - 10.1056/NEJMoa1003548

M3 - Article

VL - 363

SP - 1918

EP - 1927

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 20

ER -